Hemodynamic ABI Monitor
Recruiting
- Conditions
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 50
- Registration Number
- NCT06725108
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
Recruiting
- Conditions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 3000
- Registration Number
- NCT06705803
- Locations
- ๐บ๐ธ
The University of Chicago, Hyde Park, Illinois, United States
๐บ๐ธThe University of Cinncinatti, Cincinnati, Ohio, United States
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
Not Applicable
Not yet recruiting
- Conditions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 200
- Registration Number
- NCT06693310
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life With HIV and Substance Use
Not Applicable
Not yet recruiting
- Conditions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 900
- Registration Number
- NCT06682468
- Locations
- ๐บ๐ธ
University of Chicago Medicine, Chicago, Illinois, United States
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 35
- Registration Number
- NCT06669572
- Locations
- ๐บ๐ธ
o University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 25
- Registration Number
- NCT06663072
- Locations
- ๐บ๐ธ
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Phase 4
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 80
- Registration Number
- NCT06660862
- Locations
- ๐บ๐ธ
o University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Does Ethyl Chloride Spray Work?
Not Applicable
Not yet recruiting
- Conditions
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 300
- Registration Number
- NCT06651788
Objective Assessment of Outcomes Following Immediate Lymphatic Reconstruction / LYMPHA
Not yet recruiting
- Conditions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 90
- Registration Number
- NCT06650592
- Locations
- ๐บ๐ธ
The University o Chicago, Chicago, Illinois, United States
Genicular Nerve Block After Open Reduction Internal Fixation of Tibial Plateau
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 38
- Registration Number
- NCT06639503
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath